DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

Opportunities include integrating digital health for remote care, leveraging demographic trends, and overcoming CGM unit costs to expand access across regionsDublin, March 16, 2026 (GLOBE NEWSWIRE) -- ...

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

Researchers have found in a new study that continuous glucose monitoring (CGM) in the ICU appears to provide reliable glucose ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...

Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths - Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warni ...

People don't buy consumer wearables just to count steps anymore. They want early warnings, useful health signals, and features they can trust.

Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...